otal sales guidance is
increased by $30 million to $1.86 - $1.91 billion. This includes CNS
franchise sales of $975 - $1,000 million, pain franchise sales of $500 -
$525 million, oncology franchise sales of $155 - $180 million, and other
product sales of $200 - $225 million. Full year SG&A and R&D guidance is
$770 - $790 million and $340 - $360 million, respectively, and reflects a
$30 million increase in SG&A guidance. Adjusted net income guidance for
2008 is $346 - $353 million and basic adjusted income per common share
guidance is $5.10 - $5.20.
For the third quarter of 2008, Cephalon is introducing sales guidance
of $480 - $490 million, adjusted net income guidance of $85 - $92 million
and basic adjusted income per common share guidance of $1.25 - $1.35.
Basic adjusted income per common share guidance for both the third
quarter 2008 and full-year 2008 is reconciled below and is subject to the
assumptions set forth therein.
Cephalon's management will discuss the company's second quarter 2008
performance in a conference call with investors beginning at 5:00 p.m. U.S.
EDT today. To participate in the conference call, dial +1-913-312-9303 and
refer to conference code number 6640353. Investors can listen to the call
live by logging on to the company's website at http://www.cephalon.com and
clicking on "Investor Information," then "Webcast." The conference call
will be archived and available to investors for one week after the call.
About Cephalon, Inc.
Founded in 1987, Cephalon, Inc. is an international biopharmaceutical
company dedicated to the discovery, development and commercialization of
innovative products in four core therapeutic areas: central nervous system,
pain, oncology and addiction. A member of the Fortune 1000, Cephalon
currently employs approximately 3,000 people in the United States and
Europe. U.S. sites include the company's headquarters in Frazer,
Pennsylvania, Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Related biology technology :1
. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain2
. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant3
. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA4
. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia5
. Cephalon Quarterly Conference Call Invitation6
. Cephalon Announces Strong Third Quarter Financial Results7
. Cephalon Submits Supplemental New Drug Application for FENTORA8
. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma9
. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available10
. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain11
. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application